Download presentation
Presentation is loading. Please wait.
Published byみいか うすい Modified over 6 years ago
1
Building a Data Driven HCV Screening and Linkage-to-Care Program
A review of Norton Healthcare’s HCV screening program and our HCV+ patient population Michelle Rose, MBA Infectious Diseases/ Population Health Analyst 9/21/2018
2
Funded through a grant from Gilead Sciences:
Disclosure Funded through a grant from Gilead Sciences: Covers Project Manager, Patient Navigators, and up to 10% of Principal Investigator salary EMR modifications Grant funds do not extend past linkage-to-care 9/21/2018
3
Frontlines of Communities in the United States (FOCUS) Overview
Make routine HIV/HCV screening a standard of medical care Reduce the number of undiagnosed individuals, decrease the number of those who are diagnosed late, and ensure linkage to care and treatment Generate dialogue among healthcare systems on increasing HIV and viral hepatitis diagnoses Change public perceptions, and overcome HIV- and viral hepatitis-related stigma that may discourage testing 9/21/2018
4
Norton pre-FOCUS HCV screening practices
6,882 screened 417 AB+ RNA+ est. < 100 Linkage to Care unknown 9/21/2018
5
Analyses objectives Better understand the composition of our HCV+ patient population Identify linkage-to-care opportunities and barriers and develop actionable strategies for moving patients along the care continuum Identify data-driven opportunities for expanding HCV screening 9/21/2018
6
Year 1 data - 1 May 2016 and 30 June 2017 35,630 Screened 2,022 AB+
994 RNA+ First Quarter Year 1 Program Modifications: EMR Primary Care Modification: CDC Birth Cohort Best Practice Alerts (BPA) Quantitative PCR Reflex for all HCV AB+ screens 9/21/2018
7
Doctor’s name 9/21/2018
8
9/21/2018
9
Screening by age groups: N=35,630
9/21/2018
10
Screening by sex and race: N =35,630
9/21/2018
11
Screens ordered by site: N=35,630
9/21/2018
12
AB+ and RNA+ by age group and sex: N=2,022
9/21/2018
13
9/21/2018
14
HCV RNA+ patients by birth cohorts: N=994
9/21/2018
15
HCV seropositivity by: zip codes (with HCV highest rates) and birth cohort
9/21/2018
16
HCV seropositivity by: zip codes (with HCV highest rates) and birth cohorts
9/21/2018
17
HCV RNA+ patient status as of 1 Oct 2017: N=994
9/21/2018
18
9/21/2018
19
Proportion of HCV+ patients reaching successive stages
9/21/2018
20
Actively followed by provider - age group and sex
9/21/2018
21
On or completed HCV treatment - age group and sex
9/21/2018
22
Deceased - adjusted age group and sex: N=63
Overdoses or Bacterial Infections 9/21/2018
23
Incarcerated - age group and sex: N=106
9/21/2018
24
HCV screening by site as a predictor of patient status
9/21/2018
25
HCV seropositivity rates outside of the CDC birth cohort were significant; screening only within the birth cohort (Baby Boomers) would have resulted in missing close to 50% of the HCV infections. The BPA launched early in the study resulted in much higher rates of screening within the birth cohort. Norton should now consider an EMR modification that will significantly promote outpatient HCV screening of patients born after 1965. Primary care providers played a crucial role in positively moving HCV+ patients along the care continuum. Providers that regularly engaged with their patients to get screened and subsequently linked to specialty care had the highest HCV cure rates. 9/21/2018
26
Leverage your influence as the PCP in HCV care, treatment and cure
Screen!!!!! within and outside of the Baby Boomer birth cohort Reflex HCV positive antibody tests to quantitative PCR Communicate RNA+ tests in person and provide patient appropriate HCV literature Dedicate an HCV patient navigator Expand HCV referrals to include Infectious Disease Specialists Don’t take an initial No Thank You as a final No Thank You – perseverance matters Coordinate care with treating HCV Specialists Partner with a specialty pharmacy 9/21/2018
27
Bonus Slide 9/21/2018
28
HCV treatment approval by payor – top 10
9/21/2018
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.